Haemophilia Experiences, Results and Opportunities (HERO) study: Treatment-related characteristics of the population

Haemophilia

Volumn 21, Issue 1, 2015, Pages e26-e38

  Nugent, D ^a   Kalnins, W ^b   Querol, F ^c   Gregory, M ^d   Pilgaard, T ^e   Cooper, D L ^f   Iorio, A ^g  

^a CHILDREN S HOSPITAL OF ORANGE COUNTY   (United States)

^b German Haemophilia Society   (Germany)

^c HOSPITAL UNIVERSITARIO LA FE   (Spain)

^d Haemophilia Society   (United Kingdom)

^e NOVO NORDISK A S   (Denmark)

^f NOVO NORDISK INC   (United States)

^g MCMASTER UNIVERSITY   (Canada)

Author keywords

Access; Comprehensive care; Haemophilia; Psychosocial; Treatment

Indexed keywords

ADULT; AGED; ANKLE; ARTICLE; BLEEDING; CHEMOPROPHYLAXIS; DECISION MAKING; DISEASE CONTROL; ELBOW; FEMALE; GENERAL PRACTITIONER; HEALTH CARE UTILIZATION; HEALTH SURVEY; HEMARTHROSIS; HEMOPHILIA; HIP; HOME CARE; HUMAN; KNEE; MAJOR CLINICAL STUDY; MALE; MEDICAL SPECIALIST; MUSCLE BLEEDING; NURSE; PARENTAL ATTITUDE; PATIENT ATTITUDE; PERSONAL EXPERIENCE; PHYSIOTHERAPIST; PHYSIOTHERAPY; PRIORITY JOURNAL; PSYCHOLOGIST; PSYCHOTHERAPIST; QUALITY OF LIFE; QUANTITATIVE STUDY; RESPONSIBILITY; SELF CARE; SHOULDER; SOCIAL PSYCHOLOGY; SOCIAL WORKER; SON; SPORT; TREATMENT DURATION; WORK; ADOLESCENT; AGED, 80 AND OVER; COMPLICATION; DATA COLLECTION; HEALTH SERVICES ACCESSIBILITY; HEMOPHILIA A; HEMORRHAGE; HUMANS; MIDDLE AGED; PERCEPTION; PSYCHOLOGY; STATISTICS AND NUMERICAL DATA; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; DATA COLLECTION; FEMALE; HEALTH SERVICES ACCESSIBILITY; HEMOPHILIA A; HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; PERCEPTION; YOUNG ADULT;

EID: 84921475470     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/hae.12545     Document Type: Article

References (38)

1. World Federation of Hemophilia. World Federation of Hemophilia Report on the ANNUAL GLOBAL SURVEY 2010. Montreal, Canada: WFH, 2011.
2. World Federation of Hemophilia. World Federation of Hemophilia Report on the ANNUAL GLOBAL SURVEY 2008. Montreal, Canada: WFH, 2009.
3. Fischer K, Hermans C. The European Principles of Haemophilia Care: a pilot investigation of adherence to the principles in Europe. Haemophilia 2013; 19: 35-43.
4. Walsh CE, Valentino LA. Factor VIII prophylaxis for adult patients with severe haemophilia A: results of a US survey of attitudes and practices. Haemophilia 2009; 15: 1014-21.
5. Zappa S, McDaniel M, Marandola J, Allen G. Treatment trends for haemophilia A and haemophilia B in the United States: results from the 2010 practice patterns survey. Haemophilia 2012; 18: e140-53.
6. Ragni MV, Fogarty PJ, Josephson NC, Neff AT, Raffini LJ, Kessler CM. Survey of current prophylaxis practices and bleeding characteristics of children with severe haemophilia A in US haemophilia treatment centres. Haemophilia 2012; 18: 63-8.
7. Thornburg CD, Carpenter S, Zappa S, Munn J, Leissinger C. Current prescription of prophylactic factor infusions and perceived adherence for children and adolescents with haemophilia: a survey of haemophilia healthcare professionals in the United States. Haemophilia 2012; 18: 568-74.
8. Remor E. Predictors of treatment difficulties and satisfaction with haemophilia therapy in adult patients. Haemophilia 2011; 17: e901-5.
9. Valentino LA, Walsh CE, Reding MT, Young GA, Levendoglu-Tugal O, Cooper DL. Patient- and caregiver-reported bleeding symptoms and reasons for starting and stopping treatment with recombinant factor VIIa: analysis of the Dosing Observational Study in Haemophilia (DOSE). Haemophilia 2012; 18: 554-60.
10. Noone D, O'Mahony B, Prihodova L. A survey of the outcome of prophylaxis, on-demand or combined treatment in 20-35 year old men with severe haemophilia in four European countries. Haemophilia 2011; 17: e842-3.
11. Duncan N, Kronenberger W, Roberson C, Shapiro A. VERITAS-Pro: a new measure of adherence to prophylactic regimens in haemophilia. Haemophilia 2010; 16: 247-55.
12. Duncan NA, Kronenberger WG, Roberson CP, Shapiro AD. VERITAS-PRN: a new measure of adherence to episodic treatment regimens in haemophilia. Haemophilia 2010; 16: 47-53.
13. Cassis FRMY. Psychosocial Care for People with Hemophilia. Montreal, QC: World Federation of Haemophilia (WFH).
14. Cassis FR, Querol F, Forsyth A, Iorio A. Psychosocial aspects of haemophilia: a systematic review of methodologies and findings. Haemophilia 2012; 18: e101-14.
15. Forsyth AL, Gregory M, Nugent D et al. Haemophilia Experiences, Results and Opportunities (HERO) Study: Survey Methodology and Population Demographics. Haemophilia, 2014; 20: 44-51.
16. The EuroQol Group. EuroQol-a new facility for the measurement of health-related quality of life. Health Policy 1990; 16: 199-208.
17. Health PRUWCCiM. WHO (Five) Well-Being Index. 1998.
18. Rosen RC, Catania J, Pollack L, Althof S, O'Leary M, Seftel AD. Male Sexual Health Questionnaire (MSHQ): scale development and psychometric validation. Urology 2004; 64: 777-82.
19. Ahlberg A. Haemophilia in Sweden. VII. Incidence, treatment and prophylaxis of arthropathy and other musculo-skeletal manifestations of haemophilia A and B. Acta Orthop Scand Suppl 1965: Suppl 77:3-132.
20. Manco-Johnson MJ, Abshire TC, Shapiro AD et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 2007; 357: 535-44.
21. Feldman BM, Pai M, Rivard GE et al. Tailored prophylaxis in severe hemophilia A: interim results from the first 5 years of the Canadian Hemophilia Primary Prophylaxis Study. J Thromb Haemost 2006; 4: 1228-36.
22. Hang MX, Blanchette VS, Pullenayegum E, McLimont M, Feldman BM. Age at first joint bleed and bleeding severity in boys with severe hemophilia A: Canadian Hemophilia Primary Prophylaxis Study. J Thromb Haemost 2011; 9: 1067-9.
23. Kraft J, Blanchette V, Babyn P et al. Magnetic resonance imaging and joint outcomes in boys with severe hemophilia A treated with tailored primary prophylaxis in Canada. J Thromb Haemost 2012; 10: 2494-502.
24. Tagliaferri A, Di Perna C, Rivolta GF. Secondary prophylaxis in adolescent and adult haemophiliacs. Blood Transfus 2008; 6(Suppl 2): s17-20.
25. Tagliaferri A, Franchini M, Coppola A et al. Effects of secondary prophylaxis started in adolescent and adult haemophiliacs. Haemophilia 2008; 14: 945-51.
26. Tagliaferri A, Rivolta GF, Rossetti G, Pattacini C, Gandini G, Franchini M. Experience of secondary prophylaxis in 20 adolescent and adult Italian hemophiliacs. Thromb Haemost 2006; 96: 542-3.
27. Srivastava A, Brewer AK, Mauser-Bunschoten EP et al. Guidelines for the management of hemophilia. Haemophilia 2013; 19: e1-47.
28. Baker JR, Riske B, Voutsis M, Cutter S, Presley R. Insurance, home therapy, and prophylaxis in U.S. youth with severe hemophilia. Am J Prev Med 2011; 41: S338-45.
29. Mulders G, de Wee EM, Vahedi Nikbakht-Van de Sande MC, Kruip MJ, Elfrink EJ, Leebeek FW. E-learning improves knowledge and practical skills in haemophilia patients on home treatment: a randomized controlled trial. Haemophilia 2012; 18: 693-8.
30. Schrijvers LH, Beijlevelt-van der Zande M, Peters M, Schuurmans MJ, Fischer K. Learning intravenous infusion in haemophilia: experience from the Netherlands. Haemophilia 2012; 18: 516-20.
31. Khair K, Gibson F, Meerabeau L. The benefits of prophylaxis: views of adolescents with severe haemophilia. Haemophilia 2012; 18: e286-9.
32. Poon MC, Luke KH. Haemophilia care in China: achievements of a decade of World Federation of Hemophilia treatment centre twinning activities. Haemophilia 2008; 14: 879-88.
33. Iorio A, Marchesini E, Marcucci M, Stobart K, Chan AK. Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or B. Cochrane Database Syst Rev 2011; 9: CD003429.
34. Berntorp E, Astermark J, Baghaei F et al. Treatment of haemophilia A and B and von Willebrand's disease: summary and conclusions of a systematic review as part of a Swedish health-technology assessment. Haemophilia 2012; 18: 158-65.
35. Olivieri M, Kurnik K, Pfluger T, Bidlingmaier C. Identification and long-term observation of early joint damage by magnetic resonance imaging in clinically asymptomatic joints in patients with haemophilia A or B despite prophylaxis. Haemophilia 2012; 18: 369-74.
36. Manco-Johnson MJ, Manco-Johnson ML, Blades T et al. Long-term orthopedic effects of delaying prophylaxis in severe hemophilia A until age 6 years: results of the Joint Outcome Study Continuation (JOSc). Blood 2013; 122: Abstract 210.
37. Morfini M, Haya S, Tagariello G et al. European study on orthopaedic status of haemophilia patients with inhibitors. Haemophilia 2007; 13: 606-12.
38. Valentino LA, Mamonov V, Hellmann A et al. A randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A management. J Thromb Haemost 2012; 10: 359-67.